Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies

Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies

San Jose CA  June 25, 2015

Marybeth Gamber, Senior Regulatory Affairs Principal in Consulting Services presented at the Opal Events Medical Devices Summit West on June 25, 2015 in San Jose, CA. The attached presentation entitled, “Investigation Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies,” will focused on the FDA Early Feasibility Study (EFS) program. The intention of the EFS program is for devices that are early in their development lifecycle for which preclinical test methods are either not available or adequate to provide information to advance the device development process. Ms. Gamber discussed the background of the IDE process, the creation of the EFS program and guidance, along with the key steps and considerations to consider when pursuing this path, including lessons learned from on early interactions with the FDA in this program.

Please view the SlideShare of her presentation below.

Tags:
Marybeth Gamber
mgamber@boston-biomedical.com

Comments

No Comments

Post A Comment

BBA News and Blog

Want to be updated on the latest news and insights from our team?

You have Successfully Subscribed!

MENU